Technology News and Research

RSS

Medifacts awarded a $1.9M contract to provide cardiac safety services

MEDIFACTS INTERNATIONAL, INC., one of the largest global providers of noninvasive cardiac diagnostic services, today announced the award of a $1.9 million contract with a Global pharmaceutical company to provide comprehensive cardiac safety and efficacy services for a large late stage clinical trial.

23 Sep 2009

Research reveals balancing act between sugar-coated nanoparticles

A research team at the National Institute of Standards and Technology (NIST) studying sugar-coated nanoparticles for use as a possible cancer therapy has uncovered a delicate balancing act that makes the particles more effective than conventional thinking says they should be. Just like individuals in a crowd respecting other people's personal space, the particles work because they get close together, but not too close.

23 Sep 2009

SEA technology to increase potency of monoclonal antibodies

Seattle Genetics, Inc. announced today the introduction of its sugar engineered antibody (SEA) technology, a novel approach to increasing the potency of monoclonal antibodies through enhanced effector function. The technology will be presented today by Dennis Benjamin, Ph.D., Senior Director, Chemistry, during the Americas Antibody Congress being held in Washington, DC.

23 Sep 2009

Preclinical data on Protalix Biotherapeutics' antiTNF released

Protalix Biotherapeutics, Inc., reported today preclinical data on pr-antiTNF, a biosimilar version of etanercept (Enbrel). Produced using the Company’s proprietary ProCellEx technology, pr-antiTNF is a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), fused to the Fc component of a human antibody IgG1 domain. Pr-antiTNF has an identical amino acid sequence to Enbrel.

23 Sep 2009

Practice Fusion’s EHR offered to BioReference physicians

Practice Fusion Inc., the fastest growing electronic health record community for physicians in the United States, today announced a partnership with BioReference Laboratories, Inc. (NASDAQ:BRLI), the third largest full service laboratory in the country. The companies will collaborate to distribute Practice Fusion’s EHR to interested BioReference physicians and will integrate BioReference lab results into the Practice Fusion’s system.

23 Sep 2009

Making ACOs a permanent part of health reform will help control costs: CAPG

Leaders from California’s physicians groups are in Washington DC this week meeting with key members of Congress to offer their experience at the forefront of a key health care reform element – Accountable Care Organizations (ACOs).

23 Sep 2009

Proposed cuts can impact Ohio's health care services

The health reform bill currently pending in the House of Representatives, combined with the impact of the cuts being waved in front of Medicare-funded nursing homes -- an estimated $12 billion over 10 years -- will find Ohio's seniors in need of nursing and rehabilitative care on shaky ground.

23 Sep 2009

Bio-Path Holdings to develop liposome tumor targeting technology

Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).

23 Sep 2009

Community Hospital South implements GE Healthcare's Centricity Enterprise solution

GE Healthcare, a leading provider of healthcare information technology, announced Community Hospital South (Indianapolis) is now live with GE Centricity™ Enterprise 6.1 and Monitored Care, an integrated clinical, financial and administrative solution that helps streamline workflow and improve productivity across the continuum of care.

23 Sep 2009

Researching the causes of Alzheimer's disease

The standard explanation for what causes Alzheimer's is known as the amyloid hypothesis, which posits that the disease results from of an accumulation of the peptide amyloid beta, the toxic protein fragments that deposit in the brain and become the sticky plaques that have defined Alzheimer's for more than 100 years.

23 Sep 2009

Sterile cord blood collection bag now from PacifiCord

Dedicated to serving the private cord blood banking needs of Southern California, PacifiCord (www.pacificord.com) today announced it has secured Pall Corporation’s sterile cord blood collection bag. Since April 2006, this industry-best sterile bag has been unavailable for purchase due to prior limiting agreements with its manufacturer; no longer.

23 Sep 2009

NIH grants $3.4M to develop tools for identification of prostate cancer using MRI

Rutgers University and two collaborators have received a $3.4 million research grant to develop tools aimed at improving the identification of prostate cancer using MRI, or magnetic resonance imaging.

23 Sep 2009

Medtronic's transcatheter valves to be presented at TCT 2009

With the promise of percutaneous treatments for patients with diseased heart valves growing, Medtronic, Inc., announced today that more presentations than ever before – at least 25 – on the company’s portfolio of unique transcatheter valves will be presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009, the world’s premier annual meeting for interventional cardiologists.

23 Sep 2009

Noveko to provide antimicrobial face masks and respirators to Air Transat

Noveko International Inc. ("the Company") announces that its subsidiary Noveko Inc. ("Noveko") has won a first order from Air Transat, Canada's leading holiday travel airline, for some 500,000 Noveko(TM) antimicrobial face masks and respirators as well as for AZURO(TM) hand sanitizers.

23 Sep 2009

Civil action against BioAlliance Pharma gets rejected

BioAlliance Pharma SA (Paris:BIO) announces today that the American District Judge has granted the motion to dismiss of BioAlliance Pharma and one of its executive in response to the civil action filed by Eurofins. Eurofins filed an appeal.

23 Sep 2009

Biotime's new subsidiary to focus on clinical development and marketing therapeutic stem cell products in China

BioTime, Inc. (OTCBB:BTIM) announced today that it will organize a new subsidiary, BioTime Asia, Limited, for the purpose of clinically developing and marketing therapeutic stem cell products in the People’s Republic of China, and marketing stem cell research products in China and other countries in Asia.

23 Sep 2009

Update from Advanced Cell on pre-clinical activities for its RPE cell program

Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTC: ACTC) provided an update on pre-clinical activities in preparation of its first IND filing with the Food and Drug Administration for its retinal pigment epithelium (RPE) cell program for the treatment of various eye diseases.

23 Sep 2009

Axion Health and CHS to deliver Workforce Emergency Preparedness and Response programs

Axion HealthTM (www.axionhealth.com), a workforce health protection, emergency preparedness and response provider, today announced that it will partner with Comprehensive Health Services, Inc. (www.chsmedical.com), the industry’s largest independent provider of onsite health centers, nationwide exam programs and rapid response medical readiness teams for workforce health to deliver its ReadySetTM Program for Workforce Emergency Preparedness and Response; including the ReadySet Pandemic Program for prevention, protection and response to pandemic health threats.

23 Sep 2009

McLaren Health Care and ProTom partner to bring Proton beam therapy to Michigan

Cancer patients residing in and near Michigan are one step closer to receiving one of the most advanced forms of treatment available with a new partnership being formed between McLaren Health Care and ProTom International, a Texas-based health care technology company.

23 Sep 2009

Applied Spine Technologies’ new corporate headquarters in Connecticut

Applied Spine Technologies Inc. (www.appliedspine.com), a medical device company focused on motion preservation of the lumbar spine, announced today their plans to relocate the company to Rocky Hill, Connecticut and close their New Haven office.

23 Sep 2009